Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study

BMC Medicine

Ashkan Emadi⁶  Christian C Abnet⁷  Sanford M Dawsey⁷  Reza Malekzadeh⁵  Paolo Boffetta¹  Paul Brennan⁸  Akram Pourshams³  Hossein Poustchi³  Farhad Islami²  Farin Kamangar⁴  Arash Etemadi⁷ 

[1] Institute for Translational Epidemiology and Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA;Surveillance and Health Services Research, American Cancer Society, Atlanta, GA, USA;Liver and Pancreatobiliary Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran;Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, MD, USA;Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran;Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA;Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr, Bethesda 20859, MD, USA;International Agency for Research on Cancer, Lyon, France

关键词: Cardiovascular disease;    Cancer;    Mortality;    Rh;    ABO;    Blood group;   

Others  :  1118674
DOI  :  10.1186/s12916-014-0237-8

 received in 2014-09-04, accepted in 2014-11-12,  发布年份 2015

【 摘 要 】

Background

A few studies have shown an association between blood group alleles and vascular disease, including atherosclerosis, which is thought to be due to the higher level of von Willebrand factor in these individuals and the association of blood group locus variants with plasma lipid levels. No large population-based study has explored this association with overall and cause-specific mortality.

Methods

We aimed to study the association between ABO blood groups and overall and cause-specific mortality in the Golestan Cohort Study. In this cohort, 50,045 people 40- to 70-years old were recruited between 2004 and 2008, and followed annually to capture all incident cancers and deaths due to any cause. We used Cox regression models adjusted for age, sex, smoking, socioeconomic status, ethnicity, place of residence, education and opium use.

Results

During a total of 346,708 person-years of follow-up (mean duration 6.9 years), 3,623 cohort participants died. Non-O blood groups were associated with significantly increased total mortality (hazard ratio (HR) = 1.09; 95% confidence interval (CI): 1.01 to 1.17) and cardiovascular disease mortality (HR = 1.15; 95% CI: 1.03 to 1.27). Blood group was not significantly associated with overall cancer mortality, but people with group A, group B, and all non-O blood groups combined had increased risk of incident gastric cancer. In a subgroup of cohort participants, we also showed higher plasma total cholesterol and low-density lipoprotein (LDL) in those with blood group A.

Conclusions

Non-O blood groups have an increased mortality, particularly due to cardiovascular diseases, which may be due to the effect of blood group alleles on blood biochemistry or their effect on von Willebrand factor and factor VIII levels.

Please see related commentary http://dx.doi.org/10.1186/s12916-014-0250-y webcite.

【 授权许可】

   
2015 Etemadi et al.; licensee BioMed Central.

【 参考文献 】

• [1]Garratty G: Blood groups and disease: a historical perspective. Transfus Med Rev 2000, 14:291-301.
• [2]Jenkins PV, O’Donnell JS: ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006, 46:1836-1844.
• [3]Cserti CM, Dzik WH: The ABO blood group system and Plasmodium falciparum malaria. Blood 2007, 110:2250-2258.
• [4]Sharara AI, Abdul-Baki H, ElHajj I, Kreidieh N, Kfoury Baz EM: Association of gastroduodenal disease phenotype with ABO blood group and Helicobacter pylori virulence-specific serotypes. Dig Liver Dis 2006, 38:829-833.
• [5]Yamamoto F, Cid E, Yamamoto M, Blancher A: ABO research in the modern era of genomics. Transfus Med Rev 2012, 26:103-118.
• [6]Liumbruno GM, Franchini M: Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus 2013, 11:491-499.
• [7]He M, Wolpin B, Rexrode K, Manson JE, Rimm E, Hu FB, Qi L: ABO blood group and risk of coronary heart disease in two prospective cohort studies. Arterioscler Thromb Vasc Biol 2012, 32:2314-2320.
• [8]Franchini M, Mannucci PM: ABO blood group and thrombotic vascular disease.Thromb Haemost 2014, in press.
• [9]Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB: ABO blood group and cancer. Eur J Cancer 2010, 46:3345-3350.
• [10]Liumbruno GM, Franchini M: Hemostasis, cancer, and ABO blood group: the most recent evidence of association. J Thromb Thrombolysis 2014, 38:160-166.
• [11]Nakao M, Matsuo K, Ito H, Shitara K, Hosono S, Watanabe M, Ito S, Sawaki A, Iida S, Sato S, Yatabe Y, Yamao K, Ueda R, Tajima K, Hamajima N, Tanaka H: ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infection. Cancer Epidemiol Biomarkers Prev 2011, 20:1665-1672.
• [12]Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, Jafari E, Rakhshani N, Salahi R, Semnani S, Kamangar F, Abnet CC, Ponder B, Day N, Dawsey SM, Boffetta P, Malekzadeh R: Cohort profile: The Golestan Cohort Study–a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol 2010, 39:52-59.
• [13]Khademi H, Etemadi A, Kamangar F, Nouraie M, Shakeri R, Abaie B, Pourshams A, Bagheri M, Hooshyar A, Islami F, Abnet CC, Pharoah P, Brennan P, Boffetta P, Dawsey SM, Malekzadeh R: Verbal autopsy: reliability and validity estimates for causes of death in the Golestan Cohort Study in Iran. PLoS One 2010, 5:e11183.
• [14]Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B, Merat S, Nasseri-Moghaddam S, Semnani S, Sepehr A, Wakefield J, Møller H, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R: Socio-economic status and oesophageal cancer: results from a population-based case–control study in a high-risk area. Int J Epidemiol 2009, 38:978-988.
• [15]Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, Abaie B, Islami F, Nasseri-Moghaddam S, Etemadi A, Byrnes G, Abnet CC, Dawsey SM, Day NE, Pharoah PD, Boffetta P, Brennan P, Kamangar F: Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ 2012, 344:e2502.
• [16]Hanley JA: A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health 2001, 55:508-514.
• [17]Wu O, Bayoumi N, Vickers MA, Clark P: ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008, 6:62-69.
• [18]Carpeggiani C, Coceani M, Landi P, Michelassi C, L’Abbate A: ABO blood group alleles: a risk factor for coronary artery disease. An angiographic study. Atherosclerosis 2010, 211:461-466.
• [19]Cesena FH, da Luz PL: ABO blood group and precocity of coronary artery disease. Thromb Res 2006, 117:401-402.
• [20]Ketch TR, Turner SJ, Sacrinty MT, Lingle KC, Applegate RJ, Kutcher MA, Sane DC: ABO blood types: influence on infarct size, procedural characteristics and prognosis. Thromb Res 2008, 123:200-205.
• [21]Garrison RJ, Havlik RJ, Harris RB, Feinleib M, Kannel WB, Padgett SJ: ABO blood group and cardiovacular disease: the Framingham study. Atherosclerosis 1976, 25:311-318.
• [22]Amirzadegan A, Salarifar M, Sadeghian S, Davoodi G, Darabian C, Goodarzynejad H: Correlation between ABO blood groups, major risk factors, and coronary artery disease. Int J Cardiol 2006, 110:256-258.
• [23]Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, et al.: Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
• [24]Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, Tan X, Ye S: Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease. Circ Cardiovasc Genet 2014, 7:43-48.
• [25]Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, et al.: Myocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium: Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377:383-392.
• [26]Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, Fontcuberta J: Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000, 20:2024-2028.
• [27]Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999, 19:3071-3078.
• [28]Gandhi C, Ahmad A, Wilson KM, Chauhan AK: ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. J Thromb Haemost 2014, 12:255-260.
• [29]van Schie MC, van Loon JE, de Maat MP, Leebeek FW: Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011, 9:899-908.
• [30]Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635-641.
• [31]Tregouet DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Juhan-Vague I, Alessi MC, Tiret L, Lathrop M, Emmerich J, Morange PE: Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009, 113:5298-5303.
• [32]Heit JA, Armasu SM, Asmann YW, Cunningham JM, Matsumoto ME, Petterson TM, De Andrade M: A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012, 10:1521-1531.
• [33]Yamamoto F, McNeill PD, Hakomori S: Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 1992, 187:366-374.
• [34]Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M, Nyren O: Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010, 172:1280-1285.
• [35]Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, Mokdad A, Lozano R, Vos T, Asadi-Lari M, Sayyari AA, Murray CJ, Naghavi M: Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med 2014, 17:304-320.